These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17593008)

  • 1. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use.
    Ward KW; Lepage JF; Driot JY
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):243-56. PubMed ID: 17593008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
    Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH; Fung HB
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
    O'Brien TP
    Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
    Nafziger AN; Bertino JS
    Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
    Donnenfeld ED; Comstock TL; Proksch JW
    J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment.
    Kozai S; Wada T; Kida T; Tajika T; Sakaki H; Ohtori A
    Int J Antimicrob Agents; 2009 Dec; 34(6):561-5. PubMed ID: 19782539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS; Zhang JZ
    Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
    Paladino JA; Callen WA
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes.
    Zhang JZ; Ward KW
    J Antimicrob Chemother; 2008 Jan; 61(1):111-6. PubMed ID: 17965029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.
    Lees P
    J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of moxifloxacin as shown in animal and in vitro studies.
    McGee DH; Holt WF; Kastner PR; Rice RL
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability of phototoxic tests of fluoroquinolones in vitro.
    Zhang T; Li JL; Ma XC; Xin J; Tu ZH
    Acta Pharmacol Sin; 2003 May; 24(5):453-9. PubMed ID: 12740182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals.
    Beyerle A; Nolte MW; Solomon C; Herzog E; Dickneite G
    Toxicol Appl Pharmacol; 2014 Oct; 280(1):70-7. PubMed ID: 25102310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease.
    Shafiee A; Bucolo C; Budzynski E; Ward KW; López FJ
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1422-30. PubMed ID: 20881303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.